Journal article
Acid suppressants for managing gastro-oesophageal reflux and gastro-oesophageal reflux disease in infants: a national survey
JC Bell, FJ Schneuer, C Harrison, L Trevena, H Hiscock, AG Elshaug, N Nassar
Archives of Disease in Childhood | BMJ PUBLISHING GROUP | Published : 2018
Abstract
OBJECTIVES: To evaluate the diagnosis and management of reflux and gastro-oesophageal reflux disease (GORD) in infants aged <1 year presenting to general practitioners (GPs). DESIGN, SETTING AND PARTICIPANTS: A nationally representative, prospective, cross-sectional survey of GP activity in Australia, 2006-2016 (Bettering the Evaluation And Care of Health Study). Annually, a random sample of around 1000 GPs recorded details for 100 consecutive visits with consenting, unidentified patients. OUTCOME MEASURES: Diagnoses of reflux and GORD and their management including prescribing of acid-suppressant medicines (proton pump inhibitors (PPIs) and histamine receptor antagonists (H2RAs)) and counse..
View full abstractGrants
Awarded by National Health and Medical Research Council Career Development Fellowship
Awarded by Australia's National Health and Medical Research Council
Awarded by NHMRC Practitioner Fellowship
Funding Acknowledgements
Between April 2006 and March 2016, the BEACH program was funded by the Australian Government Department of Health, the Australian Government Department of Veterans' Affairs, AstraZeneca (Australia), Novartis Pharmaceuticals Australia, Seqirus Australia, AbbVie, Merck Sharp & Dohme (Australia), Pfizer Australia, GlaxoSmithKline Australia, Sanofi-Aventis Australia, Bayer Australia, Janssen-Cilag, Abbott Australasia, Wyeth Australia, Roche Products and the National Prescribing Service. The Murdoch Children's Research Institute is supported by the Victorian Government's Operational Infrastructure Program. NN was supported by a National Health and Medical Research Council Career Development Fellowship (APP1067066). AGE receives salary support as the HCF Research Foundation Professorial Research Fellow and holds research grants from The Commonwealth Fund and Australia's National Health and Medical Research Council (ID 1109626 and 1104136). He also receives consulting/sitting fees from Cancer Australia, the Capital Markets Cooperative Research Centre-Health Quality Program, NPS MedicineWise (facilitator of Choosing Wisely Australia), The Royal Australasian College of Physicians (facilitator of the EVOLVE program) and the Australian Commission on Safety and Quality in Health Care and as a member of the Australian Government Department of Health's Medicare Benefits Schedule Review Taskforce. HH was supported by an NHMRC Practitioner Fellowship (APP 1136222).